The first-place finish earned HeartPoint Global $20,000 in prize money. 

Will a coronary drug-coated balloon finally gain full approval from the FDA? New data presented at TCT 2023 seems to suggest it just might happen.  

All eyes were on TAVR during the first round of late-breaking clinical trials at TCT 2023 in San Francisco. Researchers shared key updates related to devices from Edwards Lifesciences, Medtronic, Boston Scientific and JenaValve Technology.

Ziad Ali, MD, discusses the mixed results of the ILUMIEN IV trial comparing OCT vs angiography alone.

Akhil Narang, MD, explained that the two technologies can be used together to deliver high-quality patient care. 

According to Shockwave, the updated IVL catheter can deliver 50% more pulses than its previous offering. 

Radial access provides interventional cardiologists with a safe, effective alternative to femoral access during peripheral artery interventions.

Even as TAVR continues to build momentum as the go-to treatment option for many patients, researchers are keeping a close eye on the long-term safety and effectiveness of SAVR.